Alemtuzumab treatment of intermediate-1 myelodysplasia patients is associated with sustained improvement in blood counts and cytogenetic remissions. - Wikidata - awgldk - TriplyDB

Alemtuzumab treatment of intermediate-1 myelodysplasia patients is associated with sustained improvement in blood counts and cytogenetic remissions.

Alemtuzumab treatment of intermediate-1 myelodysplasia patients is associated with sustained improvement in blood counts and cytogenetic remissions.

http://www.wikidata.org/entity/Q34488656

about

Immune Mechanisms in Myelodysplastic Syndrome Myelodysplastic syndromes: 2015 Update on diagnosis, risk-stratification and management Immunomodulatory treatment of myelodysplastic syndromes: antithymocyte globulin, cyclosporine, and alemtuzumab Management of lower-risk myelodysplastic syndromes without del5q: current approach and future trends.IPSS-independent prognostic value of plasma CXCL10, IL-7 and IL-6 levels in myelodysplastic syndromes Increased plasma thrombopoietin levels in patients with myelodysplastic syndrome: a reliable marker for a benign subset of bone marrow failure.Thrombocytopenia in MDS: epidemiology, mechanisms, clinical consequences and novel therapeutic strategies.The relationship between idiopathic cytopenias/dysplasias of uncertain significance (ICUS/IDUS) and autoimmunity.A phase II multicenter rabbit anti-thymocyte globulin trial in patients with myelodysplastic syndromes identifying a novel model for response prediction.Current therapy of myelodysplastic syndromes Hypomethylating agents and other novel strategies in myelodysplastic syndromes.Immunologic aspects of hypoplastic myelodysplastic syndrome.Myelodysplastic syndromes in children: where are we today?Alemtuzumab in T-cell large granular lymphocytic leukaemia: interim results from a single-arm, open-label, phase 2 study Favorable outcome of patients who have 13q deletion: a suggestion for revision of the WHO 'MDS-U' designation Immunosuppression for myelodysplastic syndrome: how bench to bedside to bench research led to success A plasma microRNA signature as a biomarker for acquired aplastic anemia.Final results of the phase II study of rabbit anti-thymocyte globulin, ciclosporin, methylprednisone, and granulocyte colony-stimulating factor in patients with aplastic anaemia and myelodysplastic syndrome Immunological derangement in hypocellular myelodysplastic syndromes.Management of lower-risk myelodysplastic syndromes: the art and evidence.Myelodysplastic syndromes: 2011 update on diagnosis, risk-stratification, and management.Failure of hypomethylating agent-based therapy in myelodysplastic syndromes.Antibodies in the treatment of aplastic anemia.Myelodysplastic syndromes: 2012 update on diagnosis, risk-stratification, and management.Emerging immunosuppressive drugs in myelodysplastic syndromes.The genetic basis of phenotypic heterogeneity in myelodysplastic syndromes.Alemtuzumab and myelodysplasia: a story of love and hate (possible alemtuzumab-induced myelodysplastic changes).Review of therapeutic options and the management of patients with myelodysplastic syndromes.Myelodysplastic syndromes: toward a risk-adapted treatment approach.Myelodysplastic syndromes: 2014 update on diagnosis, risk-stratification, and management.Update on the pharmacotherapy for myelodysplastic syndromes.Cellularity, characteristics of hematopoietic parameters and prognosis in myelodysplastic syndromes.Where Does Lenalidomide Fit in Non-del(5q) MDS?Emerging biological therapies for the treatment of myelodysplastic syndromes.Evaluation of efficacy of alemtuzumab in 5 patients with aplastic anemia and/or myelodysplastic neoplasm Hypomethylating agents (HMA) treatment for myelodysplastic syndromes: alternatives in the frontline and relapse settings.Rapidly growing non-tuberculous mycobacterial infection in a renal transplant patient after alemtuzumab induction.Expansion of effector memory regulatory T cells represents a novel prognostic factor in lower risk myelodysplastic syndrome.Single-cell RNA-seq reveals a distinct transcriptome signature of aneuploid hematopoietic cells.Unexplained severe Coombs-negative hemolytic anemia during treatment of refractory chronic lymphocytic leukemia with alemtuzumab.

P2860

Q26744500-F91D9096-ECDA-40E8-978F-A19D4C657747 Q26796240-0B743713-6F16-4E6F-9253-0C3416EF65A2 Q26864200-62EE7C5B-6EBC-4332-ACE2-8C534E87E3EF Q30235355-5BB2F944-41A8-40E4-84BB-CFA7A167AAD1 Q33397165-D90EB920-40F9-4232-B349-E02F7AE9C123 Q33405829-D0CAA914-2F73-4518-8D8F-BA9682E88338 Q33427023-9DE3327D-1007-4026-B7FE-B9C3C5984FCC Q33442467-94649E93-0708-4B9A-9155-A94B3D524234 Q33828560-8BF5F440-5263-4C03-A3DF-EC0DBE3B9D62 Q34013796-265FBD99-1C1E-4314-B2A5-4E7827690F73 Q34667051-A08799C4-04CB-4D19-934F-D90DDD303072 Q35275808-DAFB8916-2076-4DD6-9B2A-14EEB4C84BCB Q36250890-53FC8B1B-B2D2-4866-8E64-357F758CB18D Q36486302-8D2A4D66-D43E-4818-9C0E-C05B41CC7A01 Q36662033-8F9DA7A0-F0E7-4C21-BC52-5F91627B7177 Q37222206-4151D33E-19F4-4C9F-9840-58BCC993D429 Q37555805-7107AFF8-22B8-4466-9DC6-18053293110C Q37584833-9F526C74-DFC9-4DDB-A6BB-FEAE7DBDC196 Q37724605-9CD78105-B20D-4A75-8933-86DE539E03EE Q37858436-CBCD91AD-0B99-4AA5-8E22-8571161D6587 Q37877204-FC6FD187-9872-4098-89CD-E836E593AFAF Q37937816-441F33F3-A75A-4301-85E1-0886A3CFB955 Q37981576-2021EF23-5C63-4C6A-A0C9-E9C8729547E8 Q38018571-DD312113-0184-498A-9876-D509672D146E Q38060835-4E2279BB-F481-4672-8A24-C32CDD456BE1 Q38061848-37D8581E-DA55-4F13-A518-2AE338C4460B Q38069054-3D3DA2AF-429A-470F-A488-C77D3785E3B9 Q38095121-1E09C206-A67F-4167-888F-2A665C2C7298 Q38149315-64A2B4A6-ECB2-4AD3-8CC4-7E896C74885C Q38181996-F92C0ACF-2650-40A8-BA70-EE25DED36162 Q38235662-A8101A07-241E-475B-83C9-6D6E4457A34A Q38323957-0C03850F-B35F-4EE7-AE8D-C56164B2771D Q38546273-6A2D9BCD-F034-401C-B8C3-5272C1E64FF8 Q38834981-6CDC926F-26CE-41BD-8D0B-CAB380B85389 Q39289359-EC57AFD5-0E90-49B0-B3E2-93EDC998BB31 Q39413114-62AE1B33-809E-4812-9689-B59917B43DB2 Q42205422-2C1B0306-0B09-4AE4-93DA-5E2229CA631D Q42324057-18DE0E17-AD5E-476F-85A4-8113DE92D793 Q42778136-86C01ED5-164A-41AB-9662-88286CAFF5E4 Q43437611-42475F6F-C0EA-4A91-83D9-5D14A7BF8664

P2860

Alemtuzumab treatment of intermediate-1 myelodysplasia patients is associated with sustained improvement in blood counts and cytogenetic remissions.

http://www.wikidata.org/entity/Q34488656

description

2010 nî lūn-bûn

@nan

2010 թուականի Նոյեմբերին հրատարակուած գիտական յօդուած

@hyw

2010 թվականի նոյեմբերին հրատարակված գիտական հոդված

@hy

2010年の論文

@ja

2010年論文

@yue

2010年論文

@zh-hant

2010年論文

@zh-hk

2010年論文

@zh-mo

2010年論文

@zh-tw

2010年论文

@wuu

name

Alemtuzumab treatment of inter ...... ts and cytogenetic remissions.

@ast

Alemtuzumab treatment of inter ...... ts and cytogenetic remissions.

@en

Alemtuzumab treatment of inter ...... ts and cytogenetic remissions.

@nl

type

label

Alemtuzumab treatment of inter ...... ts and cytogenetic remissions.

@ast

Alemtuzumab treatment of inter ...... ts and cytogenetic remissions.

@en

Alemtuzumab treatment of inter ...... ts and cytogenetic remissions.

@nl

prefLabel

Alemtuzumab treatment of inter ...... ts and cytogenetic remissions.

@ast

Alemtuzumab treatment of inter ...... ts and cytogenetic remissions.

@en

Alemtuzumab treatment of inter ...... ts and cytogenetic remissions.

@nl

P1433

Q34488656-C78F4263-A58F-441A-85DF-28B1AF81F08F

P1476

Q34488656-FB41774C-7F8E-4B47-A1E3-BD2D150A324C

P2093

Q34488656-095A92BB-A301-42D1-8158-AF01666CE5FD

Q34488656-31CC43D9-4814-49A4-AB03-92360A0E7564

Q34488656-40235FF6-F426-4578-8CC7-588F61281DD7

Q34488656-8AD0CF23-F35E-4727-9D3F-8E34C444C75C

Q34488656-A8E74AD6-ECB9-4AFB-9854-9C6FB654B62D

Q34488656-C591FE7D-C829-43D9-8563-1D45F33E89FD

Q34488656-EC7D457D-6EEA-43F5-9004-33A2D33936B8

Q34488656-F51372E3-6CD0-4DA1-A8ED-68A2CA17CB79

Q34488656-F99C6589-82C5-4A91-A737-3EC48B849103

P2860

Q34488656-0029DFD4-046E-4B5B-9E19-474AC35603F5

Q34488656-140B20DD-54CF-4190-8FEA-95E738CEFBEB

Q34488656-182753E6-4FFE-4DE5-BC16-CF547B45021A

Q34488656-1F8C8D73-A2E3-482D-B145-01F6D057AA27

Q34488656-34901D69-C925-46AA-B27B-A3D8652F3BBB

Q34488656-40C1D6E9-48B9-4DD1-AEA4-121614F45069

Q34488656-45124C86-170B-4711-844D-1B4A517BA653

Q34488656-48FF8793-10B2-4065-A2DC-C44A97AF370C

Q34488656-58167EE4-A1DE-41CC-9937-FA71F3C079CE

Q34488656-610F2CF3-9F19-4616-84E6-CEE60DDF2E70

P304

Q34488656-37ECD013-3714-4F44-BA5B-5DE7EBA2EE34

P31

Q34488656-7DE762E3-7881-41E4-B842-5AE7ACA0CF26

P356

Q34488656-12D06A5A-B4CF-4F03-AE8C-1B862DC4E3C9

P407

Q34488656-C070B8AD-5C89-4021-A249-5AF1F12E1367

P433

Q34488656-21C30F67-45D8-4A52-86A4-72FB5CCC3419

P478

Q34488656-78DE2751-0B86-4A8C-B656-DA038F2315AB

P50

Q34488656-AED5270A-29F9-4FEA-A936-697A3CC06CDB

Q34488656-BC0E957B-9CD5-4199-B074-F7ECEC24E58D

P577

Q34488656-1A91AD03-6036-43B2-B1CC-7DE084D10B95

P698

Q34488656-204AC095-4321-4090-AA3C-CDF1CEAAE953

P921

Q34488656-015C42E6-B187-49C5-B3FF-98FDA7E77710

P932

Q34488656-832376D0-53C4-4041-A048-18F0087DE5E2

P356

JCO.2010.29.7010

P1433

Journal of Clinical Oncology

P1476

Alemtuzumab treatment of inter ...... nts and cytogenetic remissions

@en

P2093

A John Barrett

http://www.w3.org/2001/XMLSchema#string

Aarthie Shenoy

http://www.w3.org/2001/XMLSchema#string

Barbara Weinstein

http://www.w3.org/2001/XMLSchema#string

Carol Boss

http://www.w3.org/2001/XMLSchema#string

Colin O Wu

http://www.w3.org/2001/XMLSchema#string

Elaine M Sloand

http://www.w3.org/2001/XMLSchema#string

Kenneth More

http://www.w3.org/2001/XMLSchema#string

Matthew J Olnes

http://www.w3.org/2001/XMLSchema#string

Neal S Young

http://www.w3.org/2001/XMLSchema#string

P2860

Ribosomal protein S27-like, a p53-inducible modulator of cell fate in response to genotoxic stress

Efficacy of azacitidine compared with that of conventional care regimens in the treatment of higher-risk myelodysplastic syndromes: a randomised, open-label, phase III study

Sex hormones, acting on the TERT gene, increase telomerase activity in human primary hematopoietic cells

Alemtuzumab in chronic lymphocytic leukemia

The effect of treatment with Campath-1H in patients with autoimmune cytopenias.

Phase 2 study of lenalidomide in transfusion-dependent, low-risk, and intermediate-1 risk myelodysplastic syndromes with karyotypes other than deletion 5q.

Randomized controlled trial of azacitidine in patients with the myelodysplastic syndrome: a study of the cancer and leukemia group B.

A decision analysis of allogeneic bone marrow transplantation for the myelodysplastic syndromes: delayed transplantation for low-risk myelodysplasia is associated with improved outcome.

New approaches to the treatment of myelodysplasia.

Granulocyte colony-stimulating factor preferentially stimulates proliferation of monosomy 7 cells bearing the isoform IV receptor

P304

5166-5173

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1200/JCO.2010.29.7010

http://www.w3.org/2001/XMLSchema#string

P407

P433

35

http://www.w3.org/2001/XMLSchema#string

P478

28

http://www.w3.org/2001/XMLSchema#string

P50

Phillip Scheinberg

Kelsey Loeliger

P577

2010-11-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

21041705

http://www.w3.org/2001/XMLSchema#string

P921

P932

3020689

http://www.w3.org/2001/XMLSchema#string